青光眼强化治疗研究(GITS):比较强化与标准治疗对5年视野发展的随机对照试验
在瑞典2所大学医院纳入242例新发现早期或中期未治疗开角型青光眼患者,随机1:1分配至初始强化降眼压药物后行360°激光小梁成形术组或传统单药治疗组。总体分析中两组视野结局无显著差异,但事后分析显示未治疗眼压较高者从强化治疗中明确获益。
要点
- 总体分析中,强化治疗组与单药治疗组预计生命终点视野指数中位数分别为87.1%与79.3%(P = .15)。
- 进展事件在单药组为21%、强化组为11%(P = .03)。
- 事后分析显示,未治疗眼压较高者从初始强化治疗中获益更明显。
核心结论
- 总体分析中强化治疗组视野结局并未压倒性优于单药组,但事后分析显示未治疗眼压较高的患者有明确获益。
- 基于本研究结果,作者认为对诊断时未治疗眼压高的青光眼患者可考虑初始强化治疗,但无证据表明应对所有青光眼患者常规给予多药治疗。
研究设计与样本
- 随机、对照、开放标签、2中心临床试验。
- 在瑞典2所大学医院纳入242例新发现、未治疗的早期或中期开角型青光眼患者,按1:1随机分配。
主要发现
- 两组未治疗眼压中位数均为24 mm Hg;随访期间单药组眼压中位数和众数为17 mm Hg,多药治疗组为14 mm Hg。
- 单药组预计生命终点视野指数中位数为79.3%,多药治疗组为87.1%(P = .15)。
- 视野损害年进展速率单药组快于多药治疗组,年损失中位数分别为0.65和0.25个百分点单位(P = .09)。
- 进展事件发生在单药组21%和多药治疗组11%的参与者中(P = .03)。
- 不良事件报告于单药组25%和多药治疗组36%的参与者中,大多为轻度。
关键数值与推荐
- 强化方案为初始强化降眼压药物后行360°激光小梁成形术;传统方案为单药治疗,必要时增加治疗。
- 主要结局为按视野指数(VFI)测量的预计生命终点剩余视野。
- 按未治疗眼压中位数分组后,两组视野结局差异在高基线眼压参与者中更明显。
临床怎么用
- 作者认为,基于本研究结果,对诊断时未治疗眼压高的青光眼患者可考虑初始强化治疗。
- 作者指出,无证据表明应对所有青光眼患者常规给予多药治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the effect of an intensive initial intraocular pressure (IOP)-lowering treatment strategy on the progression of visual field damage. DESIGN: A randomized, controlled, open-label, 2-center clinical trial. METHODS: A total of 242 patients with newly detected early or moderate untreated open-angle glaucoma were enrolled at 2 university hospitals in Sweden. Participants were randomly allocated (1:1) to either initial treatment with intensive IOP-lowering medications followed by 360° laser trabeculoplasty (LTP), or to traditional mono-therapy, which was increased when deemed necessary. The primary study outcome of interest was the predicted remaining visual field, as measured by the visual field index (VFI) at projected end of life. RESULTS: The median untreated IOP was 24 mm Hg in both treatment groups. During follow-up, median and mode IOP were 17 mm Hg in the mono- and 14 mm Hg in the multi-treatment group. In the mono-treatment group, the median VFI at projected end of life was 79.3% and in the multi-treatment group 87.1% (P = .15). The annual rate of progression of visual field damage was faster in mono-treatment than in multi-treatment participants; median losses per year were 0.65 and 0.25 percentage units, respectively (P = .09). Progression events occurred in 21% of the mono- and in 11% of the multi-treatment participants (P = .03). Adverse events, mostly mild, were reported in 25% of the mono- and in 36% of the multi-treatment participants. Differences in visual field outcomes between treatment groups were more pronounced in participants having higher baseline IOP, defined by median split of untreated IOP values. CONCLUSIONS: In the overall analysis, the visual field outcomes were not overwhelmingly better in the multi-treatment group, but post hoc analysis showed definite benefit in patients with higher untreated IOP. Based on the results of this study, initial intensive treatment may be considered in glaucoma patients with high untreated IOP at diagnosis, although we found no evidence that multi-therapy should be given routinely to all glaucoma patients.
引用
- Bengtsson B, Heijl A, Aspberg J, et al. The Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development. Am J Ophthalmol. 2024. PMID: 38909742. doi:10.1016/j.ajo.2024.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。